3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Acrocephalosyndactylia
6
Cholangiocarcinoma
4
Neoplasm Metastasis
3
Myeloproliferative Disorders
2
Endometrial Neoplasms
2
Carcinoma, Transitional Cell
2
Stomach Neoplasms
1
Solid Tumor
1
Recurrence
1
Oligodendroglioma
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Multiple Myeloma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Eosinophilia
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Malignancies
1
Interventions
Temozolomide
3
Irinotecan
3
tozuleristide
2
selpercatinib
2
lenvatinib
2
gadobenic acid
2
avelumab
2
Radiation
2
Paclitaxel
2
Leflunomide
2
Immunotherapy
2
Gemcitabine
2
Everolimus
2
Cisplatin
2
Carboplatin
2
Cancer Vaccines
2
Bevacizumab
2
Adjuvants, Immunologic
2
ridaforolimus
1
regorafenib
1
prinomastat
1
pomalidomide
1
perillyl alcohol
1
pemigatinib
1
pembrolizumab
1
pamiparib
1
omburtamab I-131
1
irinotecan sucrosofate
1
interferon gamma-1b
1
infigratinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Central Nervous System Neoplasms
×
pemigatinib
×
Clear all
NCT05267106
2025-12-30
FIGHT-209
Incyte Corporation
Phase 2
Terminated
83 enrolled
18 charts